Target Mast cells

Version vom 8. Juli 2020, 10:09 Uhr

'bradykinin antagonists Icatibant, Noscapine

32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32526773 2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Apremilast
32449265 2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.

Montelukast
32492562 2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
32416408 2020. As a potential treatment of COVID-19: Montelukast.
32586154 2020. Montelukast's ability to fight COVID-19 infection.

Cromoglycate
32460208 2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
32581809 2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.

H1 antihistamines Famotidine
32579065 2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.
32599963 2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.

32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.